Robert B Posner
Serotonin Solutions, USA
Title: The role of oral serotonin supplementation as an adjunctive therapy to a medical weight control program
Biography
Biography: Robert B Posner
Abstract
Serotonin (5-hydroxytryptamine) is an amine neurotransmitter manufactured in the brain, platelets and GI tract. The amino acid tryptophan is converted to 5-hydroxytryptophan (5-HTP) and this is then converted to 5-hydroxytryptamine (serotonin). There are 7 classes of serotonin receptors and different subclasses of each receptor site. Serotonin imbalance has been linked to carbohydrate cravings, depression, anxiety, diabetes mellitus, seasonal affective disorder, migraine headaches, fibromyalgia and a number of other clinical conditions. There are many prescription medications for weight control, depression, anxiety and migraine headaches that target specific serotonin receptors for either stimulation (agonists), blocking stimulation (antagonists) or inhibiting the transport carrier at serotonergic synapses. Serotonin is present in food sources such as fruits and nuts, but the barriers of gastric acid degradation, oxidizing enzymes in the bloodstream and blood brain barrier issues prevent the effective use of serotonin in these food sources.
Serotonin-Plus is a patented delivery system of natural serotonin that reduces cravings for carbohydrates. A double blind, placebo controlled, cross over study was performed in 36 patients showing statistically significant improvement of weight loss during the active treatment phase compared to the placebo phase. The Serotonin-Plus dietary supplement has been used since 2002 as the unique feature of the medically supervised Serotonin-Plus weight control program. The SP Program has been expanded through doctors in 23 states in the U.S. and over 24,000 patients have been placed safely and effectively through the program. In addition to the patented Serotonin-Plus dietary supplement, the SP Program utilizes a dietary plan based on real food, weekly visits for behavioral modification and a prescription FDA-approved appetite suppressant. The 12-week protocol averages 13.63 kg (30 pounds) of weight loss in females and 18.18 kg (40 pounds) in males. The 12-week SP Program has demonstrated an over 48% reduction in the risk of developing diabetes mellitus and for those already diagnosed, 88% of the patients either discontinue medications for diabetes entirely or have a reduction to less than 50% of the dosages of their medications. Oral serotonin, when delivered via an effective delivery system, can be a very effective, adjunct to a weight control program